| Document |
Document Title |
|
WO/2019/063710A1 |
The invention relates to resorcinol-based compounds of formula (I), to the salts, solvates, optical and/or geometrical isomers thereof, to the use thereof as active agents for depigmenting, lightening and/ or bleaching keratin materials,...
|
|
WO/2019/065954A1 |
The present invention provides: a methyl 1-{2-[(3S, 4R)-1-[(3R, 4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-c
arbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethy
l)phenyl}piperidine-4-carboxylate 1/2 ethane-1,2-di...
|
|
WO/2019/066578A1 |
The present invention relates to a process for preparing a compound of formula 2 that is an intermediate used to synthesize a dipeptidyl peptidase IV enzyme-inhibiting therapeutic agent for treating diabetes mellitus, which (1) can be pr...
|
|
WO/2019/064961A1 |
Provided are: a photosensitive resin composition having high tolerance for focus depth in the formation of a punched pattern; a resist film which is a solidified product of the photosensitive resin composition; a method for forming a pat...
|
|
WO/2019/057969A1 |
The present invention relates to small molecule compounds and their use as agonists of farnesoid X receptor (FXR) and/or peroxisome proliferator activated receptor delta (PPARδ). The present invention also relates to the use of said com...
|
|
WO/2019/057946A1 |
Multi-cyclic aromatic compounds and methods of use as Factor D modulators are described herein.
|
|
WO/2019/054443A1 |
Provided are: a liquid crystal alignment film which is not susceptible to the occurrence of film separation or scratches during rubbing, and which has high voltage holding ratio and good aging resistance under high temperature high humid...
|
|
WO/2019/051396A1 |
Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity: formula (I), wherein A is N or CR...
|
|
WO/2019/042301A1 |
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...
|
|
WO/2019/040706A1 |
Methods of treating vitiligo using JAK/STAT modulating compounds are provided herein. The JAK/STAT modulating compounds may be selected from 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methylpyr
imidin-4-yl)amino)benzo[d]oxazol-2(...
|
|
WO/2019/034468A1 |
Process for the preparation of a compound with at least one monothiocarbonate group by reacting: - a compound with at least one mercaptoalcohol group and - a dialkylcarbonate, in the presence of a catalyst wherein the catalyst is a salt ...
|
|
WO/2019/026728A1 |
[Problem] The purpose of the present invention is to provide an organic EL element in which, as a highly efficient and highly durable organic EL material, various materials excelling in electron injection/transport performance, hole bloc...
|
|
WO/2019/026004A2 |
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-(
(2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to ...
|
|
WO/2019/023147A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured.The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, c...
|
|
WO/2019/023145A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, ...
|
|
WO/2019/012173A1 |
The present invention relates to piperidine derivatives as inhibitors of the PDE8A enzyme. Therefore, said compounds can be used in the production of a drug for the treatment and/or prevention of diseases involving PDE8A, such as neurode...
|
|
WO/2019/011176A1 |
Disclosed is the use of a 2-trifluoromethylbenzenesulfonamide derivative as shown in formula (I) as a URAT1 inhibitor, in particular as a therapeutic agent for a disorder related to abnormal uric acid levels.
|
|
WO/2019/000494A1 |
Provided is a fluorene-based organic electroluminescent compound, having the following structure: The compound has good thermal stability, high luminous efficiency, and high luminous purity, and can be used for manufacturing organic elec...
|
|
WO/2017/191000A9 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2018/235926A1 |
The purpose of the present invention is to provide an α, β-unsaturated amide compound or a pharmaceutically acceptable salt thereof or the like, which has anti-cancer activity or the like. An α, β-unsaturated amide compound represent...
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/214932A1 |
Small molecule compounds having aggregation-induced emission (AIE) characteristics. The compounds include organic, aromatic salts having anion-π+ interactions. In some embodiments, the anion-π+ interactions can include heavy-atom-anion...
|
|
WO/2018/216921A2 |
The present invention relates to a novel compound and an organic electroluminescent element comprising the same, and as the compound according to the present invention is used in an organic material layer, preferably a light emitting lay...
|
|
WO/2018/213140A1 |
Disclosed herein are compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (la), (lb), (Ic), (Id), (le), (If), (Ig), (...
|
|
WO/2018/213150A1 |
The application relates to phenyl- or naphthylsulfonamide derivatives of the structural formula (I). The compounds are described as inhibitors of USP30 (ubiquitin specific peptidase 30) useful for the treatment of conditions involving mi...
|
|
WO/2018/204987A1 |
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-can...
|
|
WO/2018/205948A1 |
Provided are benzoxazolinone sulfonamide derivatives that inhibit Na v1.7 activity, pharmaceutical compositions containing them and their use in therapy for the treatment of diseases mediated by Na v1.7 activity.
|
|
WO/2018/187845A1 |
The present invention relates to certain heterocyclic compounds of formula (1) that have the ability to inhibit lysine biosynthesis via the diaminopimelate biosynthesis pathway in certain organisms. As a result of this activity these com...
|
|
WO/2018/187414A1 |
The present disclosure provides compounds and methods for inhibiting mTORC2, as well as methods for treating cancers such as glioblastoma.
|
|
WO/2018/187506A1 |
Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such comp...
|
|
WO/2018/187324A1 |
The subject invention relates to a process of prepating (R)-3-hydroxybutyric acid or a salt thereof by one-step fermentation with a nonpathogenic microorganism. The fermentation of (R)-3-hydroxybutyric acid was performed by supplying wit...
|
|
WO/2018/186365A1 |
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...
|
|
WO/2018/177865A1 |
The present invention relates to the use of compounds having an anti- heparanase activity of formu la [R - L1- Ar1- L - Ar]2- X, wherein X is selected from the group consisting of SO2, C1 -C4 a lkylene, linear or branched, and wherein Ζ...
|
|
WO/2018/176343A1 |
Compounds of Formula (A), where the definition of the variables are as described in the description, as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as modulators of dysfun...
|
|
WO/2018/177857A1 |
The present invention relates to symmetrical 2-aminophenyl-benzazolyl-5-acetate compoundsof formula (I). Such compounds are endowed with an anti-heparanase activity. The present invention also relates to the use of such compounds as a me...
|
|
WO/2018/183626A1 |
Embodiments are directed to a series of novel EPAC antagonists that are designed, synthesized and evaluated in an effort to develop diversified analogues based on the scaffold of the previously identified high-throughput (HTS) hit ESI-09.
|
|
WO/2018/177860A1 |
The present invention relates to 2-(4-(4-(bromo-methoxybenzamido)benzylamino) phenyl)benzazole derivatives of formula (I) having an anti-heparanase activity. The invention also relates to the use of such compounds as a medicament, in par...
|
|
WO/2018/175185A1 |
The present invention relates to oxazolidinone Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, E, and R1 are as defined herein. The present invention also relates to compositions which comprise at ...
|
|
WO/2018/172423A1 |
The invention relates to a compound which is an indane derivative according to Formula (I), or a pharmaceutically acceptable salt thereof, [FORMULA (I)] wherein R1, R2, R3, n, R4, p¸ q, L, ׇ, X and m are as defined herein. The compound...
|
|
WO/2018/171942A1 |
It is disclosed a process for obtaining phenolic derivatives with high industrial interest in the pharmaceutical industry by using glycerol carbonate. Specifically, the process provides for a phenol substituted in position 2 to react wit...
|
|
WO/2018/101793A9 |
Provided are an amide derivative compound or a stereoisomer, derivative, solvate, or pharmaceutically acceptable salt thereof, and a use thereof according to an aspect. According to the present invention, a composition of the present inv...
|
|
WO/2018/165501A1 |
The invention provides aryl indolinyl sulfonamide and related compounds, pharmaceutical compositions, methods of promoting RORγ activity and/or increasing the amount of IL-17 in a subject, and therapeutic uses of the indolinyl sulfonami...
|
|
WO/2018/164184A1 |
Disclosed is a compound selected from among aniline derivatives represented by formula (1) and naphthalene derivatives represented by formula (2), or a salt thereof. (In the formulae, each of R1 and R2 independently represents a hydrogen...
|
|
WO/2018/152949A1 |
The present invention relates to a method for preparing optically pure (R)-4-n-propyl-dihydrofuran-2(3H)-one, and belongs to the field of chemical synthesis. The method of the present invention uses the steps of alkylation, reduction, cy...
|
|
WO/2018/155942A1 |
The present disclosure relates to a plurality of host materials and an organic electroluminescent device comprising the same. The organic electroluminescent device of the present disclosure can exhibit excellent lifespan characteristics ...
|
|
WO/2018/157043A1 |
Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.
|
|
WO/2018/156500A1 |
Methods of synthesizing polyfluorinated amino acid derivatives are disclosed, along with polyfluorinated amino acid derivatives produced from said methods, as well as compositions containing same. The synthesis methods utilize an oxazolo...
|
|
WO/2018/151470A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound according to the present disclosure is contained in an electro...
|
|
WO/2018/148745A1 |
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...
|
|
WO/2018/141854A1 |
The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity ...
|
